Immunotherapeutically-targeting IDO1 in pediatric high-grade glioma

Email Principal Investigator
picture for website.png

Derek Wainwright

CBTN Data Used


About this


Patients diagnosed with high-grade pediatric brain tumors have long-term survival rates of only 10 - 15% despite aggressive treatments with surgery and irradiation. To address this grim prognosis, cancer immunotherapy, a strategy whereby the host immune system is re-targeted/reactivated to cause tumor destruction, has recently been considered to be a potentially promising strategy. Indoleamine 2,3 dioxygenase 1 (IDO1) is an immunosuppressive enzyme that mediates the inhibition of immune cell-mediated glioblastoma (GBM) destruction. Moreover, adult GBM patients with high intratumoral IDO1 mRNA levels possess decreased overall survival. In contrast, the relevance of IDO1 remains to be explored in pediatric brain tumors. To address this knowledge gap, IDO1, in addition to other immune-modulating approaches, will be investigated in the pediatric brain tumor setting.

Ask The


Ask the scientists

What are the goals of this project?

We previously showed that increased IDO1 expression is associated with decreased adult glioblastoma patient survival. We are interested in determining its relevance in malignant pediatric brain tumors.

Specimen Data

The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.

Explore the data in these informatics portals